Benzinga

MAY 9, 2024

Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO. Hedrick, M.D.,

Marketability 45

Marketability Technology 45

Benzinga

APRIL 7, 2022

Pfizer Inc (NYSE: PFE ) shares are trading higher Thursday. The company announced the acquisition of ReViral for a total consideration of up to $525 million. Sisunatovir has been.

52

52

Benzinga

MAY 2, 2023

Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. We are excited to bring this powerful platform into Eterna. Chief Executive Officer and President of Eterna. Gregory Fiore, M.D.,

Technology 52

Technology 52

Benzinga

DECEMBER 25, 2023

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform Gracell shareholders to receive $2.00 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc.

Technology 40

Technology Marketability 40

Law 360 M&A

AUGUST 8, 2022

Pfizer Inc. will acquire sickle cell-drug company Global Blood Therapeutics in a $5.4 billion enterprise value deal shaped by legal advisers Cravath Swaine & Moore LLP, Goodwin Procter LLP and Wachtell Lipton Rosen & Katz, the companies said Monday.

Enterprise Value 40

Enterprise Value 40

Benzinga

OCTOBER 16, 2023

16, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3

Marketability 45

Marketability Finance 45

Law 360 M&A

SEPTEMBER 9, 2022

Global Blood Therapeutics Inc. billion plan to acquire the sickle cell-drug company, claiming that GBT's top brass made incomplete and misleading disclosures in an attempt to convince shareholders to sign off on the proposed deal. investors have challenged Pfizer's $5.4

40

40

Law 360 M&A

SEPTEMBER 1, 2022

Davis Polk & Wardwell LLP-led Novo Nordisk will acquire Goodwin Procter LLP-advised Forma Therapeutics Holdings Inc., which develops treatments for sickle cell disease and rare blood disorders, for a total equity value of $1.1 billion, the companies announced Thursday.

Equity 40

Equity 40

Benzinga

DECEMBER 26, 2023

26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE: BMY ) and RayzeBio, Inc. RayzeBio is a clinical-stage radiopharmaceutical therapeutics ("RPT") company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. and SAN DIEGO, Dec.

Alpha 40

Alpha Dividends Finance Equity 40

Benzinga

APRIL 11, 2024

EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. NASDAQ: ELYM ) ("Eliem") and Tenet Medicines, Inc. We believe TNT119 represents a promising clinical asset across multiple autoimmune diseases targeting markets where there is a need for improved treatment options." "We

Marketability 40

Marketability 40

Benzinga

OCTOBER 6, 2023

06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. NASDAQ: TALS ) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. About Tourmaline Bio, Inc.

Dividends 40

Dividends Banking Marketability 40

Benzinga

JANUARY 9, 2023

-Calidi's novel platform addresses a critical obstacle in traditional oncolytic virotherapy, overcoming virus inactivation through allogeneic stem cell delivery mechanism to [successfully] target a wide range of cancers, including high-grade gliomas and solid tumors. 09, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc.

Technology 40

Technology Finance Marketability 40

Benzinga

NOVEMBER 1, 2022

01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. NASDAQ: ATOS ), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. SEATTLE, Nov.

40

40

Benzinga

APRIL 14, 2023

NKGen Biotech, Inc. NKGen"), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.'s and THE WOODLANDS, Texas, April 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. .'s IV (NYSE: GFOR , GFOR.U,

Enterprise Value 40

Enterprise Value Equity Technology Marketability 40

Benzinga

AUGUST 4, 2022

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. This is an exciting time for the Company and the future Lisata. Eastern time. Mazzo, Ph.D.,

Start-ups 40

Start-ups Marketability Technology 40

Benzinga

SEPTEMBER 29, 2023

29, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. 29, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. NASDAQ: RENB ) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy has signed a definitive agreement to combine with GEDi Cube Intl Ltd.,

Technology 45

Technology Equity 45

Benzinga

SEPTEMBER 21, 2022

– Positions Company for leadership in AI-powered drug discovery –. Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results –. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. Expands iBio's immuno-oncology pipeline with three new candidates –.

40

40

Benzinga

JANUARY 8, 2024

08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., About Ambrx Biopharma, Inc. Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next-generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. billion. "We

Technology 40

Technology Equity 40

Benzinga

AUGUST 31, 2023

31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. NASDAQ: SURF ) ("Surface"), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. CAMBRIDGE, Mass.,

40

40

Benzinga

MARCH 3, 2023

SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc.,

Technology 40

Technology 40

Benzinga

NOVEMBER 6, 2022

Artrya Ltd (ASX:AYA) has passed a key milestone with the medical technology company receiving regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom. Sydney, Nov. Sydney, Nov. Click here. Click here. million tonnes at 0.9% vanadium pentoxide. million Thundering Herd convertible notes to 1 February 2024.

Technology 40

Technology 40

Benzinga

JUNE 30, 2023

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc.

Equity 40

Equity Technology 40

Benzinga

OCTOBER 27, 2022

27, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. As a company solely focused on making an impact for people with rare and genetically defined diseases, this non-equity funding provides us with increased financial flexibility to continue to advance our mission," said Brian Goff, chief executive officer at Agios. "As

Equity 40

Equity 40

Benzinga

AUGUST 31, 2022

The combined company is designed to have a diversified pipeline with multiple ‘shots-on-goal' across varying indications and therapeutic areas, built from relationships with leading research institutions. The combined company will be renamed "Ocean Biomedical, Inc." NEW YORK, Aug.

Enterprise Value 40

Enterprise Value Technology Marketability 40

Benzinga

MAY 30, 2023

May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. About Morphogenesis, Inc. TAMPA, Fla.

Technology 40

Technology Marketability 40

Benzinga

SEPTEMBER 25, 2023

25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs. TARRYTOWN, N.Y.,

Technology 40

Technology 40

Reynolds Holding

OCTOBER 5, 2022

Lucia Companies, Inc. Lee Enterprises, Inc. CytoDyn Inc. 13, 2021), which we discussed in our 2021 Year-End Securities Litigation Update, the court declined to apply both the stringent review of Blasius Industries, Inc. UIP Companies, Inc. Chris-Craft Industries, Inc. , Atlas Corp. ,

Start-ups 72

Start-ups Marketability Equity Compliance 72